Phenobarbitone: Difference between revisions
No edit summary |
No edit summary |
||
| Line 56: | Line 56: | ||
*300 mg twice daily | *300 mg twice daily | ||
|} | |} | ||
==Side Effects== | |||
Adverse drug reactions associated with the use of topiramate include: | |||
!style="text-align: left"| '''Very common''' (>10% incidence) | |||
|*sedation | |||
*hypnosis | |||
|- | |||
!style="text-align: left"| '''Common''' (1-10% incidence) | |||
|*Central nervous systems effects, such as dizziness, nystagmus and ataxia | |||
*Hyperactivity in the elderly and in children | |||
*hepatitis | |||
*Impaired cognition | |||
*Impaired memory | |||
*Depression | |||
*Prolonged use can occasionally result in folate deficiency | |||
*At high doses typical barbiturate-induced respiratory depression may become severe | |||
!style="text-align: left"| '''Rare''' (<0.1% of incidence) | |||
|*Stevens-Johnson syndrome | |||
*Suicidal ideation | |||
*Toxic epidermal necrolysis | |||
|} | |||
Phenobarbitone therapy | |||
'''Overdose | |||
Overdosage can prove fatal; toxic effects include: | |||
*Coma | |||
*Slow or shallow breathing, weak pulse | |||
*Hypotension | |||
*Renal failure | |||
Revision as of 21:31, 7 October 2020
Phenobarbital(中文: 苯巴比妥), also known as phenobarbitone or phenobarb, is a medication of the barbiturate type. It is used to control all forms of epilepsy except absence seizures. It is also used as part of the emergency management of acute seizures including status epilepticus.
It usually begins working within 5 minutes when used intravenously and 30 minutes when administered by mouth. Its effects last for between 4 hours and 2 days.
Pronunciation
Phenobarbitone 30mg
Phenobarbitone 60mg
Drug Names
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Phenobarbitone Tablet 30mg | PHEN08 | P1S1S3 |
| Phenobarbitone Tablet 60mg | PHEN09 | P1S1S3 |
Mechanism of Action
Anticonvulsant medication. It binds to GABAa receptor subunits. Through this interaction, phenobarbitone increases the flow of chloride ions into the neuron which decreases the excitability of the post-synaptic neuron. Furthermore, direct blockade of excitatory glutamate signaling also contribute to the hypnotic/anticonvulsant effect.
Dosage
The dose should be adjusted to the needs of the individual patient to achieve control of seizures; this usually requires plasma concentrations of 15 to 40 micrograms/ml. However, plasma-drug concentration monitoring is less useful than with other drugs because tolerance occurs.
| Epilepsy | By Mouth
ADULT:
CHILD 1 month – 11 years:
CHILD 12 – 17 years:
|
|---|---|
| Status epilepticus | By intravenous injection
ADULT:
By slow intravenous injection CHILD 1 month – 11 years:
CHILD 12 – 17 years:
|
Side Effects
Adverse drug reactions associated with the use of topiramate include:
!style="text-align: left"| Very common (>10% incidence) |*sedation
- hypnosis
|- !style="text-align: left"| Common (1-10% incidence) |*Central nervous systems effects, such as dizziness, nystagmus and ataxia
- Hyperactivity in the elderly and in children
- hepatitis
- Impaired cognition
- Impaired memory
- Depression
- Prolonged use can occasionally result in folate deficiency
- At high doses typical barbiturate-induced respiratory depression may become severe
!style="text-align: left"| Rare (<0.1% of incidence) |*Stevens-Johnson syndrome
- Suicidal ideation
- Toxic epidermal necrolysis
|}
Phenobarbitone therapy
Overdose
Overdosage can prove fatal; toxic effects include:
- Coma
- Slow or shallow breathing, weak pulse
- Hypotension
- Renal failure
